We are live on ! Find out more
FMI

Foundation Medicine, Inc.
FMI

Delisted

FMI was delisted on the 30th of July, 2018.

157 hedge funds and large institutions have $1.86B invested in Foundation Medicine, Inc. in 2018 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more funds holding in top 10

Funds holding in top 10: 37 (+4)

88% more capital invested

Capital invested by funds: $986M → $1.86B (+$871M)

66% more call options, than puts

Call options by funds: $87.8M | Put options by funds: $52.8M

32% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 41

16% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 38

9% more funds holding

Funds holding: 144157 (+13)

Holders
157
Holders Change
+13
Holders Change %
+9.03%
% of All Funds
3.59%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.16%
New
54
Increased
44
Reduced
38
Closed
41
Calls
$87.8M
Puts
$52.8M
Net Calls
+$34.9M
Net Calls Change
-$33.1M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$200M +$8.26M +90,921 +7%
GGHC
2
Gilder Gagnon Howe & Co
New York
$183M -$4.21M -46,347 -3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$175M +$29.9M +329,708 +35%
State Street
4
State Street
Massachusetts
$119M +$5.51M +60,706 +8%
Chevy Chase Trust
5
Chevy Chase Trust
Maryland
$111M -$6.22M -68,479 -8%
CC
6
Casdin Capital
New York
$93.6M +$15M +165,000 +32%
Baillie Gifford & Co
7
Baillie Gifford & Co
United Kingdom
$55.3M +$1.26M +13,843 +4%
Morgan Stanley
8
Morgan Stanley
New York
$52.1M +$24.5M +269,219 +240%
JP Morgan Chase
9
JP Morgan Chase
New York
$50.5M +$33.2M +365,992 +9,705%
BCM
10
Beryl Capital Management
California
$47M +$31.2M +343,489 New
GF
11
Gabelli Funds
New York
$40.1M +$26.6M +293,109 New
AA
12
AQR Arbitrage
Connecticut
$36.8M +$24.4M +268,929 New
GCL
13
Glazer Capital LLC
New York
$36.5M +$24.3M +267,045 New
PCM
14
Peregrine Capital Management
Minnesota
$29.7M -$2.2M -24,203 -10%
Northern Trust
15
Northern Trust
Illinois
$28.9M +$2.27M +24,968 +13%
WIC
16
Water Island Capital
New York
$28.3M +$18.8M +207,000 New
Bank of America
17
Bank of America
North Carolina
$27.5M +$16M +176,222 +717%
GI
18
GAMCO Investors
Connecticut
$25.4M +$16.8M +185,500 New
Citigroup
19
Citigroup
New York
$23.7M +$12.9M +142,566 +468%
Goldman Sachs
20
Goldman Sachs
New York
$23.3M +$9.78M +107,685 +171%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$22.3M +$67.8K +747 +0.5%
Fidelity Investments
22
Fidelity Investments
Massachusetts
$20.4M -$243K -2,672 -2%
Fidelity International
23
Fidelity International
Bermuda
$19.9M +$13.2M +145,589 New
Norges Bank
24
Norges Bank
Norway
$18.8M +$3.42M +37,641 +38%
Deutsche Bank
25
Deutsche Bank
Germany
$17.6M +$5.7M +62,715 +95%

FMI Hedge Fund Activity: Q2 2018 in Review

157 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Foundation Medicine, Inc. (FMI) for Q2 2018, worth a combined $1.86B — up 88% from $986M a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new FMI positions and 41 closed out — a net gain of 13 holders — while 44 added to existing stakes and 38 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $33.2M. The largest seller was Oppenheimer & Co, cutting an estimated $63.6M.

  • 157 institutional investors held Foundation Medicine, Inc. (FMI) as of Q2 2018, up from 144 in Q1 2018.
  • Funds reported $1.86B of Foundation Medicine, Inc. stock for Q2 2018, up 88% quarter-over-quarter.
  • 54 funds opened new Foundation Medicine, Inc. positions in Q2 2018 and 41 closed out, a net change of +13 holders.
  • The largest Foundation Medicine, Inc. buyer in Q2 2018 was JP Morgan Chase, an estimated $33.2M added.
  • The largest Foundation Medicine, Inc. seller in Q2 2018 was Oppenheimer & Co, an estimated $63.6M sold.

Based on aggregated 13F filings for Q2 2018.